Xenon Pharmaceuticals Inc. (XENE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Xenon Pharmaceuticals Inc... (XENE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

39.72

1.47 (3.84%)

At close: Jan 14, 2025, 3:59 PM

39.65

-0.16%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	27.99
Market Cap	3.03B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.81
PE Ratio (ttm)	-14.13
Forward PE	n/a
Analyst	Buy

Ask	44.4
Volume	494,933
Avg. Volume (20D)	391,768
Open	38.45
Previous Close	38.25
Day's Range	38.08 - 39.81
52-Week Range	35.53 - 50.99
Beta	undefined

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 5, 2014

Employees 251

Stock Exchange NASDAQ

Ticker Symbol XENE

Website https://www.xenon-pharma.com

Analyst Forecast

According to 7 analyst ratings, the average rating for XENE stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 38.49% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Xenon Pharmaceuticals Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $310.00K, reflecting a n/a YoY growth and earnings per share of -0.86, making a 34.38% increase YoY.

News

1 month ago · zacks.com

Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

2 months ago · seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President a...